Ann: Clinical CBD program expands with the Lambert Initiative, page-22

He also spoke a great deal about the use of cbg? I think it was. It's another form of cannabinoid that looks like it has great potential, and I think Avecho has been involved in it.

Yes, CBG- cannabigerol.

If you go back to May’s AGM presentation, it was noted in the Chairman’s Address that AVE has already developed TPM-enhanced topical and oral dosage forms for CBD, THC, CBG, CBC and CBN.

And in the upcoming clinical trials mentioned in the slide presentation, topical CBG was earmarked for a Phase 2 trial in osteoarthritis with the Lambert Initiative, which was supposed to commence sometime this year. It was said that they were already working on the trial documentation in May.

CBG is the parent compound of CBD and THC but it’s a minor cannabinoid so likely to be more expensive than CBD.

Like CBD, CBG doesn’t make you high and it shares some of the same effects as CBD, although CBG’s effects are broader.

Both CBD and CBG have a potential anti-inflammatory effect. CBD is thought to have an effect on anxiety whereas CBG is thought to have a potential effect on depression. CBG has also demonstrated potential neuroprotective properties and effect against inflammatory GI disorders such as IBD and colitis.